GDC-0575

• Description :

  GDC-0575 (ARRY-575, RG7741) is a highly-selective oral small-molecule Chk1 inhibitor with an IC50 of 1.2 nM.

• Product Name Alternative :

  ARRY-575; RG7741

• UNSPSC :

  12352005

• Hazard Statement :

  H302

• Target :

  Checkpoint Kinase (Chk)

• Type :

  Reference compound

• Related Pathways :

  Cell Cycle/DNA Damage

• Applications :

  Cancer-Kinase/protease

• Field of Research :

  Cancer

• Assay Protocol :

  https://www.medchemexpress.com/GDC-0575.html

• Concentration :

  10mM

• Purity :

  99.50

• Solubility :

  DMSO : 100 mg/mL (ultrasonic) |H2O : < 0.1 mg/mL

• Smiles :

  O=C(C1CC1)NC2=CNC3=NC=C(Br)C(N4C[C@H](N)CCC4)=C32

• Molecular Formula :

  C16H20BrN5O

• Molecular Weight :

  378.27

• Precautions :

  H302

• References & Citations :

  [1]Oo ZY, et al. Endogenous Replication Stress Marks Melanomas Sensitive to CHEK1 Inhibitors In Vivo. Clin Cancer Res. 2018 Mar 13. doi: 10.1158/1078-0432.CCR-17-2701.|[2]Laroche-Clary A, et al. CHK1 inhibition in soft-tissue sarcomas: biological and clinical implications. Ann Oncol. 2018 Apr 1;29 (4) :1023-1029.|[3]Di Tullio A, et al. The combination of CHK1 inhibitor with G-CSF overrides cytarabine resistance in human acute myeloid leukemia. Nat Commun. 2017 Nov 22;8 (1) :1679.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category :

  Reference compound1

• Clinical Information :

  Phase 1

• Citation 01 :

  Mol Cancer Res. 2020 Jan;18 (1) :91-104.|Mol Cancer. 2024 Apr 29;23 (1) :86.|Nat Commun. 2020 Jan 8;11 (1) :123. |Neurotherapeutics. 2022 Mar;19 (2) :570-591.|Research Square Preprint. 2024 Nov 06.|bioRxiv. 2023 Feb 7.

• CAS Number :

  [1196541-47-5]